DRUGS & SUPPLEMENTS

Uricont TU

advertisement
How long you have been taking the medicine?

Uricont TU uses



Warnings and Precautions, Central Nervous System Effects (5.5)       07/2015

1 INDICATIONS AND USAGE

Uricont TU 3% (oxybutynin) gel 3% is a muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see  Clinical Studies (14) ].

Uricont TU 3% is a muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)

2 DOSAGE AND ADMINISTRATION

The recommended dosage is three pumps of Uricont TU 3% (84 mg/day) applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs. Apply immediately after actuating the dose.  Application sites may be rotated to reduce the potential for local site reactions [see  Adverse Reactions (6.1) ]. Uricont TU 3% is for topical application only and should not be ingested.

Wash hands immediately after product application. Patients should cover the application site with clothing after the gel has dried if direct skin-to-skin contact at the application site is anticipated [see  Warnings and Precautions (5.3) ].

  • Apply three pumps of Uricont TU 3% (84 mg) once daily to clean and dry, intact skin on the abdomen, or upper arms/shoulders, or thighs. (2)

  • Application site may be rotated if necessary. (2)

  • Uricont TU 3% is for topical application only and should not be ingested. (2)
advertisement

3 DOSAGE FORMS AND STRENGTHS

Uricont TU 3% is a homogeneous, colorless to slightly colored gel 3%. 

 Gel; 3% (3)

4 CONTRAINDICATIONS

The use of Uricont TU 3% is contraindicated in patients with the following conditions:

  • Urinary retention [see  Warnings and Precautions (5.1) ].

  • Gastric retention [see  Warnings and Precautions (5.2) ].

  • Uncontrolled narrow-angle glaucoma [see  Warnings and Precautions (5.8) ].
  • Urinary retention (4)

  • Gastric retention (4)

  • Uncontrolled narrow-angle glaucoma (4)

5 WARNINGS AND PRECAUTIONS

  • Urinary Retention: Caution should be exercised in patients with clinically significant bladder outflow obstruction because of urinary retention risk.

  • Gastrointestinal Disorders: Use with caution in patients with gastroesophageal reflux and/or those taking drugs that can cause or exacerbate esophagitis and in patients with decreased intestinal motility or gastrointestinal obstructive disorders because of the risk of gastric retention. (5.2)

  • Skin Transference: Advise patients to cover the application site with clothing if skin-to-skin contact at the application site is anticipated. Wash hands immediately after product application. (5.3)

  • Flammable Gel: Contains alcohol-based gel. Avoid open fire or smoking until the gel has dried. (5.4)

  • Central Nervous System Effects: Somnolence has been reported with drugs containing Uricont TU. Advise patients not to drive or operate heavy machinery until they know how Uricont TU 3% affects them. (5.5)

  • Myasthenia Gravis: Administer Uricont TU 3% with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction. (5.6)

  • Angioedema: Angioedema has been reported with oral Uricont TU use. If symptoms of angioedema occur, discontinue Uricont TU 3% and initiate appropriate therapy. (5.7)

  • Controlled Narrow-Angle Glaucoma: Administer Uricont TU 3% with caution in patients being treated for narrow-angle glaucoma. (5.8)

5.1 Urinary Retention

Use Uricont TU 3% with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.

5.2 Use in Patients with Gastrointestinal Disorders

Use Uricont TU 3% with caution in patients with gastrointestinal obstructive disorders because of the risk of gastric retention.

Uricont TU 3%, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis or intestinal atony.

Uricont TU 3% should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs that can cause or exacerbate esophagitis.

5.3 Skin Transference

Transfer of Uricont TU to another person can occur when vigorous bare skin-to-skin contact is made with the application site. To minimize the potential transfer of Uricont TU from treated skin to another person, patients should cover the application site with clothing after the gel has dried if direct skin-to-skin contact at the application site is anticipated [see  Clinical Pharmacology (12.3) ]. Patients should wash their hands immediately after application of Uricont TU 3%.

5.4 Flammable Gel

Uricont TU 3% is an alcohol-based gel and is therefore flammable. Avoid open fire or smoking until gel has dried. 

5.5 Central Nervous System Effects

Drugs containing Uricont TU are associated with anticholinergic central nervous system effects. A variety of CNS anticholinergic effects have been reported, including headache, dizziness, somnolence, confusion and hallucinations . Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment. Advise patients not to drive or operate heavy machinery until they know how Uricont TU 3% affects them. If a patient experiences anticholinergic CNS effects, drug discontinuation should be considered.

5.6 Myasthenia Gravis

Administer Uricont TU 3% with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction. 

5.7 Angioedema

Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oral Uricont TU.  In the event of angioedema, Uricont TU containing product should be discontinued and appropriate therapy promptly provided.

5.8 Controlled Narrow-Angle Glaucoma

Administer Uricont TU 3% with caution in patients being treated for narrow-angle glaucoma. 

advertisement

6 ADVERSE REACTIONS

Most common adverse reactions are dry mouth, and application site reactions. (6.1)


To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.

The safety of Uricont TU 3% was evaluated in 626 patients (210 randomized to Uricont TU 3% 56 mg/day, 214 randomized to Uricont TU 3% 84 mg/day and 202 randomized to placebo) during a randomized, placebo-controlled, double-blind, 12-week clinical efficacy and safety study. A subset of these 626 patients (N = 77) participated in the 24-week open-label safety extension that followed the placebo-controlled study. Of the 77 patients in the safety extension, 24 were randomized to placebo gel during the double-blind, placebo-controlled 12-week study. In the combined double-blind, placebo-controlled study and the open-label safety extension, a total of 441 patients were exposed to at least one dose of Uricont TU 3%. 364 patients received at least 12 weeks of Uricont TU 3% treatment and 66 patients received an additional 24 weeks of Uricont TU 3% treatment during the open-label safety extension. The study population primarily consisted of women (87%) of Caucasian descent (87%) with an average age of 59 years who had overactive bladder with urge urinary incontinence.

Table 1 lists adverse reactions (ARs), regardless of causality, that were reported in the randomized, double-blind, placebo-controlled 12-week study at an incidence greater than placebo and in greater than 3% of patients treated with Uricont TU 3%.

Overall, 672 ARs were experienced by 51.9% of patients. Majority of the ARs were mild to moderate in intensity. The AR most commonly reported was dry mouth which was experienced by a greater proportion of patients in the Uricont TU group than the placebo group (26 patients [12.1%] in the Uricont TU 84 mg group, 10 patients [5.0%] in the placebo group). Application site erythema was the next most commonly reported AR (8 patients [3.7%] in the Uricont TU 84 mg group and 2 patients [1.0%] in the placebo group). Other commonly reported ARs experienced by more patients in the Uricont TU groups compared with placebo were application site rash (7 patients [3.3%] in the Uricont TU 84 mg group and 1 patient [0.5%] in the placebo group); application site pruritus (6 patients [2.8%] in the Uricont TU 84 mg group and 1 patient [0.5%] in the placebo group).  The overall rate of application site adverse reactions of any kind was 14.2% in patients receiving Uricont TU 3% as compared to 3.7% in patients receiving placebo.  Other cholinergic AEs < 2% in occurrence include dry eyes and blurred vision.

There were no deaths during the study. There were no clinically meaningful changes in vital signs, laboratory values, or ECG examinations over the course of the study.

 Treatment Group
Preferred Term*     Uricont TU

84 mg/day

(N = 214)

 Placebo

(N = 202)

n (%) n (%)
     Dry mouth  26 (12.1)  10 (5.0)
     Application site erythema                 8 (3.7)  2 (1.0)
     Application site rash  7 (3.3)  1 (0.5)

*  Each patient is counted only once within each treatment, body system and preferred term. All percentages are based on number of patients in the ITT population within each treatment group as denominator.

During the 24-week open-label safety extension, the most commonly reported ARs were urinary tract infection and nasopharyngitis reported in 4 patients each (5.2%), followed by conjunctivitis and application site erythema (both occurred in 3 patients [3.9%]). One patient prematurely discontinued due to the application site erythema and pruritus (both considered to be of mild severity).

6. 2   Po s t m a r k e t ing   E x perie n ce

The following adverse reactions have been identified during post approval use of GELNIQUE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Nervous System Disorders: dizziness, somnolence, confusion

Psychiatric Disorders: hallucinations

advertisement

7 DRUG INTERACTIONS

No specific drug-drug interaction studies have been performed with Uricont TU 3%.

  • Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, and blurred vision and other anticholinergic pharmacological effects. (7.1)

7.1 Other Anticholinergics

The concomitant use of Uricont TU 3% with other anticholinergic (antimuscarinic) agents may increase the frequency and/or severity of dry mouth, blurred vision, and other anticholinergic pharmacological effects. 

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B.

There are no adequate and well-controlled studies of topical or oral Uricont TU use in pregnant women. Reproduction studies using Uricont TU chloride in the hamster, rabbit, rat, and mouse have shown no evidence of impaired fertility or harm to the fetus. The safety of Uricont TU 3% administration to women who are or who may become pregnant has not been established. Therefore, Uricont TU 3% should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards. 

8.2 Labor and Delivery

Uricont TU 3% has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.

8.3 Nursing Mothers

It is not known whether Uricont TU is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Uricont TU 3% is administered to a nursing woman.

8.4 Pediatric Use

The safety and effectiveness of Uricont TU 3% have not been established in pediatric patients. 

8.5 Geriatric Use

Of the 424 patients exposed to Uricont TU 3% in the randomized, double-blind, placebo-controlled 12-week study, 182 patients were 65 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients.

8.6 Renal Impairment

Patients with renal impairment received Uricont TU 3% during clinical trials. These trials were not designed to determine whether there were differences in safety or effectiveness in patients with or without impaired renal function. 

8.7 Hepatic Impairment

Patients with hepatic impairment received Uricont TU 3% during clinical trials. These trials were not designed to determine whether there were differences in safety or effectiveness in patients with or without impaired hepatic function. 

advertisement

10 OVERDOSAGE

Overdosage with Uricont TU has been associated with anticholinergic effects including central nervous system excitation, flushing, fever, dehydration, cardiac arrhythmia, vomiting, exhaustion, heat sensitivity, and urinary retention. Oral ingestion of 100 mg Uricont TU chloride in association with alcohol has been reported in a 13-year-old who experienced memory loss, and in a 34-year-old who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine. Both patients recovered fully with symptomatic treatment. If overexposure occurs, monitor patients until symptoms resolve.

11 DESCRIPTION

Uricont TU is an antispasmodic, antimuscarinic agent. Uricont TU 3% is a topical, homogeneous, very lightly to moderately opalescent, translucent colorless to slightly colored gel, without particles. The product is a hydroalcoholic gel containing 30 mg Uricont TU per gram of gel. Uricont TU 3% is available in a 0.92 gram (1 mL) unit dose that contains 28 mg Uricont TU. Uricont TU is delivered as a racemate of R- and S-isomers. Chemically, Uricont TU base is d, l (racemic) 4-(Diethylamino)-2-butynyl (±)-α-phenylcyclohexaneglycolate.

The empirical formula of Uricont TU base is C22H31NO3. Its structural formula is:

Distribution

Uricont TU is widely distributed in body tissues following systemic absorption. The volume of distribution was estimated to be 193 L after intravenous administration of 5 mg Uricont TU chloride.

Metabolism

Uricont TU is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Metabolites include N-desethyloxybutynin (DEO), which is pharmacologically active and phenylcyclohexylglycolic acid, which is pharmacologically inactive.

Transdermal administration of Uricont TU bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyloxybutynin metabolite. Only small amounts of CYP3A4 are found in skin, limiting pre-systemic metabolism during transdermal absorption. The AUC ratio of N-desethyloxybutynin metabolite to parent compound following multiple transdermal applications is approximately 1:1 for Uricont TU 3%. The apparent half-life was approximately 30 hours.

Excretion

Uricont TU undergoes extensive hepatic metabolism, with less than 0.1% of the administered dose excreted unchanged in the urine. Less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.

Person-to-Person Transference

The potential for dermal transfer of Uricont TU from a treated person to an untreated person was evaluated in a single-dose study where subjects dosed with Uricont TU 3% engaged in vigorous contact with an untreated partner for 15 minutes, either with (N = 14 couples) or without (N = 14 couples) clothing covering the application area. The untreated partners not protected by clothing demonstrated low detectable plasma concentrations of Uricont TU (mean Cmax = 0.65 ng/mL). Only one of the 14 untreated subjects participating in the clothing-to-skin contact regimen had very low measurable Uricont TU plasma concentrations (Cmax = 0.06 ng/mL) during the 24 hours following contact with treated subjects; Uricont TU was not detectable with the remaining 13 untreated subjects. Regardless of the low exposure observed in this study, patients should avoid skin-to-skin contact with partners after applying the gel.

Use of Sunscreen

The effect of sunscreen on the absorption of Uricont TU when applied 30 minutes before or 30 minutes after Uricont TU 3% application was evaluated in a single-dose randomized crossover study (N = 20). Concomitant application of sunscreen, either before or after Uricont TU 3% application, had no effect on the systemic exposure of Uricont TU.

Showering

The effect of showering on the absorption of Uricont TU was evaluated in a randomized, steady-state crossover study under conditions of no shower, or showering 1, 2 or 6 hours after Uricont TU 3% application (N = 22). The results of the study indicate that showering one hour after administration does not affect the overall systemic exposure to Uricont TU.

Race

The effect of race on the pharmacokinetics of Uricont TU 3% has not been studied.

Geriatric Patients

Available data suggest that there are no significant differences in the pharmacokinetics of Uricont TU based on geriatric status in patients following administration of Uricont TU 3% [see  Use in Specific Populations (8.5) ].

Pediatric Patients

The pharmacokinetics of Uricont TU and N-desethyloxybutynin following application of Uricont TU 3% has not been evaluated in individuals younger than 18 years of age [see Use in Specific Populations (8.4) ].

Gender

Available data suggest that there are no significant differences in the pharmacokinetics of Uricont TU based on gender in healthy volunteers following administration of Uricont TU 3%.

Renal Impairment

There is limited experience with the use of Uricont TU 3% in patients with renal insufficiency [see  Use in Specific Populations (8.6) ].

Hepatic Impairment

There is limited experience with the use of Uricont TU 3% in patients with hepatic insufficiency [see  Use in Specific Populations (8.7) ].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

A 24-month study in rats at dosages of Uricont TU chloride of 20, 80, and 160 mg/kg showed no evidence of carcinogenicity. These doses are approximately 6, 25, and 50 times the maximum exposure in humans taking an oral dose, based on body surface area. Uricont TU chloride showed no increase of mutagenic activity when tested in Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae, and Salmonella typhimurium test systems. Reproduction studies with Uricont TU chloride in the mouse, rat, hamster, and rabbit showed no evidence of impaired fertility.

14 CLINICAL STUDIES

The efficacy and safety of Uricont TU 3% were evaluated in a single randomized, double-blind, placebo-controlled, multicenter 12-week study in patients with urinary frequency and urge and mixed urinary incontinence with a predominance of urge incontinence episodes.  This was followed by an open-label safety extension. Key entry criteria included adults with overactive bladder (OAB) symptoms for at least 3 months who were either treatment-naïve or had demonstrated a beneficial response to anticholinergic treatment for OAB. Subjects were randomly assigned to receive 84 mg/day Uricont TU, 56 mg/day Uricont TU, or placebo. A total of 214 patients received 84 mg/day Uricont TU, 210 patients received 56 mg/day Uricont TU, and 202 patients received placebo gel. The majority of patients were Caucasian (87%) and female (87%), with a mean age of 59 years (range: 19 to 89 years). The primary efficacy endpoint was the change from baseline to week 12 in the number of urinary incontinence episodes (UIE) per week, as determined from a 3‑day patient daily diary.

Patients treated with Uricont TU 3% (84 mg) experienced a statistically significant decrease in the number of urinary incontinence episodes per week from baseline to endpoint (the primary efficacy endpoint) compared with placebo (p = 0.0445) and patients treated with the 56 mg dose did not show statistically significant efficacy.  Statistically significant improvements in daily urinary frequency (p = 0.0010) and urinary void volume (p < 0.0001) were also seen with Uricont TU 3% (84 mg) relative to placebo.  The mean difference from placebo for Uricont TU 3% (84 mg) was -2.3 for urinary incontinence episodes per week in a group of patients with a mean of greater than 40 incontinence episodes per week at baseline.  Mean and median change from baseline in weekly incontinence episodes (primary endpoint), daily urinary frequency, and urinary void volume (secondary endpoints) between placebo and Uricont TU 3% are summarized in Table 3.

 

Parameter 

Placebo

(N = 202) 

 GELNIQUE 3% (84 mg/day)

(N = 214)

 Mean (SD)  Median  Mean (SD)  Median
     Weekly Urinary Incontinence Episodes
 Baseline  45.8 (31.87)  40.9  43.6 (27.90)  37.3
 Reduction  -18.1 (28.81)  -14.0  -20.4 (24.39)  -16.4
 Mean difference [GELNIQUE 3% – placebo] (SE)  -2.3 (2.65)
 P-valuevs. placebo  0.0445 
     Daily Urinary Frequency
 Baseline  11.5 (3.34)  11.0  11.3 (2.87)  10.7
 Reduction  -1.9 (3.34)  - 1.7  - 2.6 (2.66)  - 2.3
Mean difference [GELNIQUE 3% - placebo] (SE)  - 0.7 (0.30)
 P-value† vs. placebo  0.0010§  
     Urinary Void Volume (mL)
 Baseline  184.5 (85.71)  173.4  196.9 (88.11)  189.2
 Increase  9.8 (64.98)  5.7  32.7 (77.25)  26.6
 Mean difference [GELNIQUE 3% – placebo] (SE)  23.0  (7.24)
 P-value† vs. placebo  < 0.0001§  

 Last-Observation-Carried-Forward imputation for missing data

 P-value is based on ANCOVA analysis on rank-transformed data

 Comparison is significant if p ≤ 0.05

§  Comparison is significant if p ≤ 0.0125, adjusting for multiplicity

16 HOW SUPPLIED/STORAGE AND HANDLING

Uricont TU 3% (oxybutynin) gel 3% is supplied in a metered-dose pump dispenser composed of an inner aluminum laminated foil liner encased in a rigid plastic bottle with a plastic cap. The nozzle of the pump dispenser is sealed by a removable cap attached to the actuator by a plastic string.

How Supplied

NDC 52544-041-54   100 mL (92 g) metered pump dispenser containing 90 metered 0.92 g (1 mL) pumps delivering 28 mg Uricont TU per pump actuation.

Storage

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). See USP controlled room temperature. Protect from moisture and humidity.

17 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Patient Information)

Instructions for Use

Inform patients of the following:

  • Uricont TU 3% is for topical application only and should not be ingested.  Keep out of reach of children.

  • Uricont TU 3% should be applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs.

  • Do not use any Uricont TU 3% that came out while priming.

  • Apply immediately after actuating the dose.  

  • Application sites may be rotated to reduce the potential for local site reactions.

  • Uricont TU 3% should not be applied to recently shaved skin surfaces. Avoid skin with open sores, wounds, irritation, scars, and tattoos.

  • Do not apply the gel to the breasts or genital area.

  • Discard used pump dispensers in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.

  • Wash hands immediately after product application.

  • Do not shower or immerse the application site in water for 1 hour after product application.

  • Cover the application sites with clothing if skin-to-skin contact at the application site is anticipated.

  • Alcohol based gels are flammable. Avoid open fire or smoking until the gel has dried.

  • If you get the gel in your eyes, thoroughly rinse your eyes right away with warm, clean water to flush out any gel. Seek medical attention if needed.

Important Anticholinergic Adverse Reactions

Patients should be informed that anticholinergic (antimuscarinic) agents, such as Uricont TU 3%, may produce clinically significant adverse reactions related to anticholinergic pharmacological activity. Heat prostration (due to decreased sweating) can occur when anticholinergics such as Uricont TU 3% are used in a hot environment. Because anticholinergic (antimuscarinic) agents, such as Uricont TU 3%, may produce dizziness or blurred vision, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until this product's effects have been determined. Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic (antimuscarinic) agents such as Uricont TU 3%. 

For all medical inquiries contact:

ACTAVIS

Medical Communications

Parsippany, NJ 07054

1-800-272-5525

Distributed By:

Actavis Pharma, Inc.

Parsippany, NJ 07054 USA

Content Updated: July 2015

FDA-approved patient labeling

Patient Information

Uricont TU [Gel-nēk] 3%

(oxybutynin) gel 3%

Topical

Important: For use on the skin only (topical). Do not get Uricont TU 3% in or near your eyes, nose, or mouth.

Read this Patient Information carefully before you use Uricont TU 3% and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.

What is Uricont TU 3%?

Uricont TU 3% is a prescription medicine used to treat the symptoms of overactive bladder including:

  • a strong need to urinate with leaking or wetting accidents (urge urinary incontinence)

  • a strong need to urinate right away (urgency)

  • urinating often (frequency) 

It is not known if Uricont TU 3% is safe or effective in children.

Who should not use Uricont TU 3%?

Do not use Uricont TU 3% if:

  • Your bladder does not empty or does not empty completely when you urinate (urinary retention).

  • Your stomach empties slowly or incompletely after a meal (gastric retention).

  • You have high pressure in your eye (uncontrolled narrow-angle glaucoma).

  • You have an allergy to Uricont TU or any of the ingredients in GELNIQUE 3%.  See the end of this leaflet for a complete list of ingredients in Uricont TU 3%.

Talk to your healthcare provider before taking this medicine if you have any of these conditions.

What should I tell my doctor before using Uricont TU 3%?

Before you use Uricont TU 3%, tell your doctor if you:

  • have problems emptying your bladder completely

  • have stomach problems including:

    -  constipation or difficulty in emptying your bowels

    -  inflamed bowels (ulcerative colitis)

    -  inflammation of the tube between your mouth and stomach (gastric reflux disease or esophagitis)

  • have generalized muscle weakness (myasthenia gravis)

  • are pregnant or are planning to become pregnant. It is not known if Uricont TU 3% will harm your unborn baby.

  • are breastfeeding or plan to breastfeed. It is not known if Uricont TU 3% passes into your breast milk. Talk to your doctor about the best way to feed your baby if you use Uricont TU 3%.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Uricont TU 3% may affect the way other medicines work, and other medicines may affect how Uricont TU 3% works.

Especially tell your doctor if you take:

  • medicines used to treat osteoporosis (Bisphosphonates)

  • other medicines used to treat overactive bladder (Anticholinergic)

Ask your doctor if you are not sure if your medicine is one listed above.

Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.

How should I use Uricont TU 3%?

Uricont TU 3% is for skin use only.

  • Use Uricont TU 3% exactly as your doctor tells you to use it.

  • Uricont TU 3% should only be applied to dry intact skin on your stomach (abdomen), upper arms, or thighs.

  • Do not put Uricont TU 3% on recently shaved skin, open sores, scars, tattoos, or skin with rashes.

  • Do not put Uricont TU 3% on your breasts or genital area.

  • Uricont TU 3% contains alcohol and is flammable. Avoid fire, flames, or smoking until the product has dried.

  • Cover the application site with clothing after the gel has dried, if skin-to-skin contact between another person and the application site is expected.

  • After applying Uricont TU 3%, wash your hands with soap and water right away.

  • Uricont TU 3% may be used with sunscreen.

  • If you get Uricont TU 3% in your eyes: Rinse your eyes well right away with clean and warm water. Seek medical attention if needed.

How to use the Uricont TU 3% pump:

You must prime the pump before you use it for the first time.

To prime the pump:

  • To prime the Uricont TU 3% pump, hold the pump upright and fully press down (depress) the pump 4 times. Now Uricont TU 3% is ready to use.

  • Do not use any product that came out while priming.

Applying Uricont TU 3%:

1. Selecting your application site:

Apply Uricont TU 3% only to 1 of the shaded areas shown in the figure below:.

  • stomach area (abdomen)

  • upper arms

  • shoulders

  • thighs

  • Wash the area where Uricont TU 3% will be applied with mild soap and water. Allow the area to dry completely.

  • Wash your hands with soap and water.

  • Application sites may be rotated to reduce the potential for local site reactions.

2. Dispensing your dose of Uricont TU 3%:

  • Place your hand under the pump.  Press the pump all the way down 3 times . You can also place the pump right over the application site then press the pump all the way down 3 times to dispense your dose .

  • You should apply Uricont TU 3% right after you dispense your dose.

  • Wash your hands with soap and water right away.

What should I avoid while using Uricont TU 3%?

  • Do not take a bath, swim, shower, exercise, or get the application site wet for 1 hour after you apply your dose.

  • Uricont TU 3% can cause dizziness or blurred vision. Do not drive, operate heavy machinery, or do other dangerous activities until you know how Uricont TU 3% affects you.

  • You should not drink alcohol while using Uricont TU 3%. It can increase your chances of getting serious side effects.

What are the possible side effects of Uricont TU 3%?

The most common side effects of Uricont TU 3% include:

  • dry mouth

  • urinary tract infections

  • dry eyes

  • blurry vision

  • redness, rash, itching, pain at the application site

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Uricont TU 3%. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

How should I store Uricont TU 3%?

  • Store Uricont TU 3% at room temperature between 68ºF to 77ºF (20ºC to 25ºC).

Keep Uricont TU 3% and all medicines out of the reach of children.

General information about the safe and effective use of Uricont TU 3%.

Medicines are sometimes prescribed for conditions that are not mentioned in the patient information leaflet. Do not use Uricont TU 3% for a condition for which it was not prescribed. Do not give Uricont TU 3% to other people, even if they have the same symptoms you have. It may harm them.

This Patient Information leaflet summarizes the most important information about Uricont TU 3%. If you would like more information about Uricont TU 3%, talk with your doctor. You can ask your pharmacist or doctor for information about Uricont TU 3% that is written for health professionals.

For more information go to www.gelnique.com or call 1-800-272-5525.

What are the ingredients in Uricont TU 3%?

Active ingredient: Uricont TU

Inactive ingredients: diethylene glycol monoethyl ether, NF; alcohol, USP; hydroxypropyl cellulose, NF; propylene glycol, NF; butylated hydroxytoluene, NF; HCl 0.1 M, NF; and purified water, USP.

This Patient Information has been approved by the U.S. Food and Drug Administration.

For all medical inquiries contact:

ACTAVIS

Medical Communications

Parsippany, NJ 07054

1-800-272-5525

Distributed By:

Actavis Pharma, Inc.

Parsippany, NJ 07054 USA

Content Updated: January 2013

219404-01

How to use the Uricont TU 3% pump Figure A Figure B Figure C

Uricont TU pharmaceutical active ingredients containing related brand and generic drugs:

infoActive ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.


Uricont TU available forms, composition, doses:

infoForm of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.


Uricont TU destination | category:

infoDestination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.


Uricont TU Anatomical Therapeutic Chemical codes:

infoA medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.


Uricont TU pharmaceutical companies:

infoPharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.


advertisement

References

  1. Dailymed."OXYBUTYNIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. "oxybutynin". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  3. "oxybutynin". http://www.drugbank.ca/drugs/DB0106... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Uricont TU?

Depending on the reaction of the Uricont TU after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Uricont TU not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Uricont TU addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sDrugs.com conducted a study on Uricont TU, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Uricont TU consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 15 here

The information was verified by Dr. Arunabha Ray, MD Pharmacology

© 2002 - 2018 "sDrugs.com". All Rights Reserved